ZYBERNO
Stock Report
Updated Jun 6, 2026

Repare Therapeutics Inc. (RPTX)

Healthcare • NASDAQ

$2.65

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Repare Therapeutics Inc. (RPTX) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-57.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-171.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Repare Therapeutics Inc. (RPTX) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RPTX generated -$76.45M in Owner Earnings. Reinvestment rate: 2.6%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.65
Market Cap:$113.86M

Valuation Multiples (2)

P/B Ratio:0.99x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$41.38M
B. Profitability Assessment

Return Metrics (5)

ROA:-50.0%
Reinvestment Rate:2.6%
Fundamental Growth Rate (g):-4.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$63.77
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:111.2%
Latest Earnings Filed:2025-11-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:10.71x
Quick Ratio:10.71x
Cash Ratio:6.27x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x
Debt-to-Equity Ratio:0.02x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:112,806,000.00
Cash And Cash Equivalents:72,825,000.00
Long Term Debt:$0.00
Net Debt:-$72.48M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$76.21M

Bottom Line Performance (3)

-$72.20M
Income Before Tax:-$71.44M
Ebitda Ttm:-73,606,000.00

Operating Expenses (5)

Operating Expenses:99,407,000.00
R And D Expense:66,550,000.00
Sga Expense:24,530,000.00
Income Tax Expense:$763.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$126.75M
Current Assets:$124.43M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:11,620,000.00
Current Liabilities:11,620,000.00
Long Term Debt:$0.00
Short Term Debt:$342.00K

Equity & Capital (3)

Equity:$115.13M
Retained Earnings:-$461.33M
Common Stock:490,487,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,334,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,392,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$117.51M-$76.45M

Investment Activities (2)

Investing Cash Flow:$28.79M
Capital Expenditures Ttm:0.00

Financing Activities (3)

Financing Cash Flow:$79.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,606,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.70
-$1.69
Earnings Per Share Ttm:-$1.68

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.78

Book Value & Capital (2)

Book Value Per Share:$2.68
Cash Per Share:1.69

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$76.45M

Damodaran Growth Analysis (2)

Reinvestment Rate:2.6%
Fundamental Growth Rate (g):-4.5%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-16.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:RPTX
Company Name:Repare Therapeutics Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:42.97M
Shares Outstanding Basic:42.97M
Shares Outstanding Diluted:43.05M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-06 06:36:55 UTC
Data Timestamp:2026-06-06T06:36:55.505511
Scroll to Top